Abstract
Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain “immunogenic” forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain “danger” signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed.
Keywords: Chemotherapy, chemomodulation, chemoimmunomodulation, immunostimulation, immunosuppression, paclitaxel
Current Medicinal Chemistry
Title:ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Volume: 19 Issue: 12
Author(s): M. R. Shurin, H. Naiditch, D. W. Gutkin, V. Umansky and G. V. Shurin
Affiliation:
Keywords: Chemotherapy, chemomodulation, chemoimmunomodulation, immunostimulation, immunosuppression, paclitaxel
Abstract: Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain “immunogenic” forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain “danger” signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed.
Export Options
About this article
Cite this article as:
R. Shurin M., Naiditch H., W. Gutkin D., Umansky V. and V. Shurin G., ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents, Current Medicinal Chemistry 2012; 19 (12) . https://dx.doi.org/10.2174/092986712800099785
DOI https://dx.doi.org/10.2174/092986712800099785 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Breast Cancer Risks in Premenopausal Women: A Review
Current Women`s Health Reviews GnRH-Analogues for Ovarian Protection in Childhood Cancer Patients: How Adult Hypotheses are Relevant in Prepubertal Females
Current Drug Targets Regulating miRNAs Expression by Resveratrol: Novel Insights based on Molecular Mechanism and Strategies for Cancer Therapy
Current Molecular Pharmacology Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Metabolic Action of Thyroid Hormones: Insights from Functional and Proteomic Studies
Current Proteomics Editorial: Teratology and Reproductive Toxicology of Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Learning from Metabolic Networks: Current Trends and Future Directions for Precision Medicine
Current Medicinal Chemistry Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Parental Perceptions and Concerns Related to the Consequences of Pediatric Obesity: Feeling or Real Problem?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Clinical Implications of Patient-Provider Agreements in Opioid Prescribing
Current Drug Safety Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry